Jun 23, 2025 · Glucagon-like peptide-1 (GLP-1) receptor agonists are a well-established treatment option for obesity and type 2 diabetes. However, there is a growing need for additional options to …

Dec 12, 2025 · A NEW class of oral drugs selectively targeting the β2 adrenergic receptor (β2AR) through a GRK2-biased pathway offers potential advances in the treatment of type 2 diabetes and …

Dec 7, 2025 · Researchers have developed a new oral drug that boosts metabolic activity in muscle rather than altering appetite like GLP-1 drugs. Early trials suggest it improves blood sugar control …

Jun 1, 2025 · The treatment of Type 2 diabetes is undergoing rapid transformation, with 2025 bringing promising new solutions for millions of patients. Breakthroughs in pharmaceuticals, digital health …

Dec 9, 2025 · For years, medical treatments for obesity and type 2 diabetes have focused on the brain and gut. Drugs in the glucagon like peptide 1 family reduce appetite and help people lose weight, yet …

Oct 17, 2024 · Groundbreaking research presented at UEG Week 2024 introduces a promising new treatment approach for type 2 diabetes (T2D) that has the potential to greatly reduce or even …

May 28, 2025 · Breakthroughs in type 2 diabetes treatment for 2025—from dual-acting drugs to digital therapeutics and CGM advances that improve outcomes.

Dec 10, 2025 · Diabetes goes beyond just glucose control, and recent advancements in research are enhancing drug development for the disease.

Apr 11, 2025 · From expanding treatment options to groundbreaking research, progress is happening. With each breakthrough, we move closer to better care, improved quality of life and—one day—a cure.

Oct 15, 2025 · Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes